Seeking Alpha
Profile| Send Message|
( followers)  

By: Ahmed Ishtiaq

Abbott Laboratories (NYSE:ABT) has taken a new shape after the spinoff. After the separation of AbbVie (ABBV), we will now have a clear idea of how profitable are the nutritionals, devices, diagnostics, and established pharmaceuticals segments. At the moment, Abbott is not as profitable as some of its competitors. The margins are quite high in the industry; however, Abbott has not been able to exploit the opportunity. Nonetheless, the company reported impressive earnings for the fourth quarter of 2012. Abbott exceeded the market expectations by $0.01 per share. We decided to perform a fair value analysis for Abbott using out discounted earnings model.

As of January 31, 2013, ABT stock was trading at around $36.39, with a 52-week range of $33.33 - $38.52. It has a market cap of about $53.6 billion. The trailing twelve-month P/E ratio of 8.1 is slightly lower than the forward P/E ratio of 9.2. P/B, P/S, and P/CF ratios stand at 1.9, 1.4, and 5.8, respectively. The operating margin is 19.7% while the net profit margin is 16.6%.

Abbott has a 3-star rating from Morningstar. The majority of analysts covering Abbott have a strong buy recommendation for the stock, and they expect the stock to outperform the sector. Wall Street has diverse opinions about the company's future. The average five-year annualized growth forecast estimate is 9%.

We can estimate Abbott's fair value using a discounted earnings plus equity model as follows.

Discounted Earnings plus Equity Model

This model is primarily used for estimating the returns from long-term projects. It is also frequently used to price fair-valued IPOs. The methodology is based on discounting the present value of the future earnings to the current period:

V = E0 + E1 /(1+r) + E2 /(1+r)2 + E3/(1+r)3 + E4/(1+r)4 + E5/(1+r)5+ Disposal Value

V = E0 + E0 (1+g)/(1+r) + E0(1+g)2/(1+r)2 + … + E0(1+g)5/(1+r)5 + E0(1+g)5/[r(1+r)5]

The earnings after the last period act as a perpetuity that creates regular earnings:

Disposal Value = D = E0(1+g)5/[r(1+r)5] = E5 / r

While this formula might look scary for many of us, it easily calculates the fair value of a stock. All we need is the current period earnings, earnings growth estimate, and the discount rate. To be as objective as possible, I use Morningstar data for my estimates. You can set these parameters as you wish, according to your own diligence.

Valuation

Historically, the average return of the DJI has been around 11% (including dividends). Therefore, I will use 11% as my discount rate.

In order to smooth the results, I will also take the average of ttm EPS along with the mean EPS estimate for the next year. The average EPS for Abbott is $1.92.

Wall Street holds diversified opinions on the company's future. While analysts tend to impose subjective opinions on their estimates, the average analyst estimate is a good starting point. Average five-year growth forecast is 9%. Book value per share is $17.27.

Fair Value Estimator

V0

E0

$1.85

V1

E0 (1+g)/(1+r)

$1.82

V2

E0((1+g)/(1+r))2

$1.78

V3

E0((1+g)/(1+r))3

$1.75

V4

E0((1+g)/(1+r))4

$1.72

V5

E0((1+g)/(1+r))5

$1.69

D

E0(1+g)5/[r(1+r)5]

$15.36

BV

Equals

$17.27

Fair Value Range

Lower Boundary

$25.97

Upper Boundary

$43.24

Potential

27.62%

(You can download FED+ Fair Value Estimator, here.)

I decided to add the book value per share so that we can distinguish between a low-debt and debt-loaded company. The lower boundary does not include the book value. According to my 5-year discounted-earnings-plus-book-value model, the fair-value range for ABT is between $25.97 and $43.24 per share. At a price of about $33.80, Abbott is trading at a price within its fair value range. The stock still has up to 27% upside potential to reach its fair value maximum.

Comparison with Peers

Abbott peers include Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE) and Novartis (NYSE:NVS). The table below lists some important metrics for comparison.

ABT

JNJ

PFE

NVS

P/E

8.1

24.3

21.2

17.4

P/B

1.9

3.2

2.5

2.4

P/S

1.3

3.1

3.3

2.9

EPS Growth

-1.20%

-8.60%

1.90%

1.80%

Operating Margin

19.70%

23.80%

26.50%

20.00%

Net Margin

16.60%

12.90%

15.60%

16.50%

ROE TTM

25.30%

13.60%

11.30%

14.10%

Debt to Equity

0.40

0.20

0.40

0.20

Source: Morningstar

Abbott is currently trading at a discount compared to its peers. EPS growth figures are poor for almost all the participants in the industry. However, Abbott has the worst operating margin compared to its peers. On the other hand, net margin for the company is better than its peers. Furthermore, the debt-to-equity ratio is in line with the industry.

Summary

Abbott has to improve its margins as the company is currently falling behind its competitors. Our valuation model indicates that there is substantial upside potential in the stock. There are a lot of growth opportunities in the market, which the company needs to exploit. I believe the separation of operation will allow the company to focus better. As a result, the operational efficiency of Abbott will improve. At the current price levels, Abbott represents an attractive investment opportunity.

Source: How Much Is Abbott Labs Worth?